Ulrich Kintscher

List of Publications by Year
in descending order

91 papers	5,060 citations	147801 31 h-index	91884 69 g-index
95 all docs	95 docs citations	95 times ranked	6969 citing authors

#	Article	IF	Citations
1	Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. Clinical Research in Cardiology, 2023, 112, 197-202.	3.3	11
2	Pharmacological inhibition of adipose tissue adipose triglyceride lipase by Atglistatin prevents catecholamine-induced myocardial damage. Cardiovascular Research, 2022, 118, 2488-2505.	3.8	20
3	Wt1 haploinsufficiency induces browning of epididymal fat and alleviates metabolic dysfunction in mice on high-fat diet. Diabetologia, 2022, 65, 528-540.	6.3	3
4	Novel nonâ€steroidal mineralocorticoid receptor antagonists in cardiorenal disease. British Journal of Pharmacology, 2022, 179, 3220-3234.	5.4	65
5	Assessment of Myocardial Microstructure in a Murine Model of Obesity-Related Cardiac Dysfunction by Diffusion Tensor Magnetic Resonance Imaging at 7T. Frontiers in Cardiovascular Medicine, 2022, 9, 839714.	2.4	5
6	Finerenone Reduces Renal RORÎ³t Î³Î´ T Cells and Protects against Cardiorenal Damage. American Journal of Nephrology, 2022, 53, 552-564.	3.1	6
7	ACE2 and SARS-CoV-2: Tissue or Plasma, Good or Bad?. American Journal of Hypertension, 2021, 34, 274-277.	2.0	9
8	Fat-body brummer lipase determines survival and cardiac function during starvation in Drosophila melanogaster. IScience, 2021, 24, 102288.	4.1	11
9	eIF5A hypusination, boosted by dietary spermidine, protects from premature brain aging and mitochondrial dysfunction. Cell Reports, 2021, 35, 108941.	6.4	56
10	Hypertrophy-Reduced Autophagy Causes Cardiac Dysfunction by Directly Impacting Cardiomyocyte Contractility. Cells, 2021, 10, 805.	4.1	8
11	Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a. International Journal of Molecular Sciences, 2021, 22, 5437.	4.1	24
12	Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenolâ€Induced Cardiac Damage. Journal of the American Heart Association, 2021, 10, e019473.	3.7	4
13	Adipose tissueâ€“heart crosstalk as a novel target for treatment of cardiometabolic diseases. Current Opinion in Pharmacology, 2021, 60, 249-254.	3.5	6
14	Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders âˆ' New perspectives for combination therapy. Pharmacological Research, 2021, 172, 105859.	7.1	37
15	Depletion of cardiac cardiolipin synthase alters systolic and diastolic function. IScience, 2021, 24, 103314.	4.1	4
16	Cardioprotective Effects of Palmitoleic Acid (C16:1n7) in a Mouse Model of Catecholamine-Induced Cardiac Damage Are Mediated by PPAR Activation. International Journal of Molecular Sciences, 2021, 22, 12695.	4.1	6
17	Spontaneous Degenerative Aortic Valve Disease in New Zealand Obese Mice. Journal of the American Heart Association, 2021, 10, e023131.	3.7	5
18	Obesity-related hypoxia via miR-128 decreases insulin-receptor expression in human and mouse adipose tissue promoting systemic insulin resistance. EBioMedicine, 2020, 59, 102912.	6.1	52

#	Article	IF	Citations
19	Development and implementation of blood pressure screening and referral guidelines for German community pharmacists. Journal of Clinical Hypertension, 2020, 22, 1807-1816.	2.0	4
20	Plasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System. Hypertension, 2020, 76, e34-e36.	2.7	57
21	Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes. Scientific Reports, 2020, 10, 14061.	3.3	8
22	Myocardial Infarction After High-Dose Catecholamine Applicationâ€"A Case Report From an Experimental Imaging Study. Frontiers in Cardiovascular Medicine, 2020, 7, 580296.	2.4	1
23	Speckle-tracking echocardiography combined with imaging mass spectrometry assesses region-dependent alterations. Scientific Reports, 2020, 10, 3629.	3.3	12
24	The Role of Adipose Triglyceride Lipase and Cytosolic Lipolysis in Cardiac Function and Heart Failure. Cell Reports Medicine, 2020, 1, 100001.	6.5	27
25	Serelaxin Improves Regional Myocardial Function in Experimental Heart Failure: An In Vivo Cardiac Magnetic Resonance Study. Journal of the American Heart Association, 2020, 9, e013702.	3.7	7
26	â€œDear Doctorâ€•Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription. Deutsches Ärzteblatt International, 2020, 117, 687-688.	0.9	2
27	Characterization of Myocardial Microstructure and Function in an Experimental Model of Isolated Subendocardial Damage. Hypertension, 2019, 74, 295-304.	2.7	23
28	Accurate assessment of LV function using the first automated 2D-border detection algorithm for small animals - evaluation and application to models of LV dysfunction. Cardiovascular Ultrasound, 2019, 17, 7.	1.6	11
29	Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenoneâ€™s Antifibrotic Activity. Hypertension, 2018, 71, 599-608.	2.7	149
30	Sex Differences in Cardiac Mitochondria in the New Zealand Obese Mouse. Frontiers in Endocrinology, 2018, 9, 732.	3.5	17
31	Evaluation of a commercial multi-dimensional echocardiography technique for ventricular volumetry in small animals. Cardiovascular Ultrasound, 2018, 16, 10.	1.6	21
32	AT ₂ R (Angiotensin AT2 Receptor) Agonist, Compound 21, Prevents Abdominal Aortic Aneurysm Progression in the Rat. Hypertension, 2018, 72, e20-e29.	2.7	26
33	The cytoskeleton in â€˜couch potato-ismâ€™: Insights from a murine model of impaired actin dynamics. Experimental Neurology, 2018, 306, 34-44.	4.1	2
34	Adipose tissue ATGL modifies the cardiac lipidome in pressure-overload-induced left ventricular failure. PLoS Genetics, 2018, 14, e1007171.	3.5	42
35	PCSK9 regulates the chemokine receptor CCR2 on monocytes. Biochemical and Biophysical Research Communications, 2017, 485, 312-318.	2.1	36
36	High-Fat Diet Induces Unexpected Fatal Uterine Infections in Mice with aP2-Cre-mediated Deletion of Estrogen Receptor Alpha. Scientific Reports, 2017, 7, 43269.	3.3	6

#	Article	IF	Citations
37	Importance of 5/6-aryl substitution on the pharmacological profile of 4Ê¹-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1Ê¹-biphenyl]-2-carboxylic acid derived PPARÎ³ agonists. European Journal of Medicinal Chemistry, 2017, 126, 590-603.	5.5	8
38	Application of Speckle-Tracking Echocardiography in an Experimental Model of Isolated Subendocardial Damage. Journal of the American Society of Echocardiography, 2017, 30, 1239-1250.e2.	2.8	25
39	AT1-receptor blockade attenuates outward aortic remodeling associated with diet-induced obesity in mice. Clinical Science, 2017, 131, 1989-2005.	4.3	23
40	Cardiovascular magnetic resonance feature tracking in small animals â€“ a preliminary study on reproducibility and sample size calculation. BMC Medical Imaging, 2017, 17, 51.	2.7	13
41	Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy. Journal of Cardiovascular Pharmacology, 2016, 67, 402-411.	1.9	59
42	New telmisartan-derived PPARÎ³ agonists: Impact of the 3D-binding mode on the pharmacological profile. European Journal of Medicinal Chemistry, 2016, 124, 138-152.	5.5	22
43	Inhibition of Src homology 2 domainâ€containing phosphatase 1 increases insulin sensitivity in highâ€fat dietâ€induced insulinâ€resistant mice. FEBS Open Bio, 2016, 6, 179-189.	2.3	12
44	Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. European Heart Journal, 2016, 37, 24-34.	2.2	512
45	Metabolic Effects of AT2R Stimulation inÂAdipose Tissue. , 2015, , 119-123.		0
46	Benefit of Blood Pressure Control in Diabetic Patients. Current Hypertension Reports, 2015, 17, 50.	3.5	4
47	Adipose Tissue Lipolysis Promotes Exercise-induced Cardiac Hypertrophy Involving the Lipokine C16:1n7-Palmitoleate. Journal of Biological Chemistry, 2015, 290, 23603-23615.	3.4	49
48	Enhanced insulin signaling in density-enhanced phosphatase-1 (DEP-1) knockout mice. Molecular Metabolism, 2015, 4, 325-336.	6.5	23
49	Angiotensin Type 2 Receptor Stimulation Ameliorates Left Ventricular Fibrosis and Dysfunction via Regulation of Tissue Inhibitor of Matrix Metalloproteinase 1/Matrix Metalloproteinase 9 Axis and Transforming Growth Factor Î²1 in the Rat Heart. Hypertension, 2014, 63, e60-7.	2.7	72
50	Sex- and age-dependent effects of Gpr30 genetic deletion on the metabolic and cardiovascular profiles of diet-induced obese mice. Gene, 2014, 540, 210-216.	2.2	38
51	The Individualized Obesity Paradox. Journal of the American College of Cardiology, 2014, 63, 786-787.	2.8	1
52	Sex differences in exercise-induced cardiac hypertrophy. Pflugers Archiv European Journal of Physiology, 2013, 465, 731-737.	2.8	32
53	Targeting density-enhanced phosphatase-1 (DEP-1) with antisense oligonucleotides improves the metabolic phenotype in high-fat diet-fed mice. Cell Communication and Signaling, 2013, 11, 49.	6.5	9
54	Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. Journal of Molecular Medicine, 2013, 91, 811-823.	3.9	69

#	Article	IF	Citations
55	Sex and Sex Hormoneâ€"Dependent Cardiovascular Stress Responses. Hypertension, 2013, 61, 270-277.	2.7	21
56	Sex-Specific Differences in Type 2 Diabetes Mellitus and Dyslipidemia Therapy: PPAR Agonists. Handbook of Experimental Pharmacology, 2013, , 387-410.	1.8	24
57	And in the endâ€"Telmisartan directly binds to PPARÎ³. Hypertension Research, 2012, 35, 704-705.	2.7	2
58	High-Mobility Group A1 Protein. Circulation Research, 2012, 110, 394-405.	4.5	11
59	A Polymorphic Microsatellite Repeat within the ECE-1c Promoter Is Involved in Transcriptional Start Site Determination, Human Evolution, and Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 16807-16820.	3.6	17
60	Characterization of Telmisartanâ€Derived PPARÎ³ Agonists: Importance of Moiety Shift from Positionâ€…6 toâ€…5 on Potency, Efficacy and Cofactor Recruitment. ChemMedChem, 2012, 7, 1935-1942.	3.2	6
61	Reuptake Inhibitors of Dopamine, Noradrenaline, and Serotonin. Handbook of Experimental Pharmacology, 2012, , 339-347.	1.8	18
62	Sexual Dimorphic Regulation of Body Weight Dynamics and Adipose Tissue Lipolysis. PLoS ONE, 2012, 7, e37794.	2.5	55
63	High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-Activated Receptor-Î³ Target Genes in Patients With the Metabolic Syndrome. Hypertension, 2011, 58, 725-732.	2.7	31
64	Sex differences in physiological cardiac hypertrophy are associated with exercise-mediated changes in energy substrate availability. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H115-H122.	3.2	56
65	Characterization of new PPARÎ³ agonists: Benzimidazole derivativesâ€"importance of positions 5 and 6, and computational studies on the binding mode. Bioorganic and Medicinal Chemistry, 2010, 18, 5885-5895.	3.0	26
66	PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovascular Diabetology, 2010, 9, 64.	6.8	52
67	Female sex and estrogen receptor-Î² attenuate cardiac remodeling and apoptosis in pressure overload. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 298, R1597-R1606.	1.8	205
68	Metabolic impact of estrogen signalling through ERalpha and ERbeta. Journal of Steroid Biochemistry and Molecular Biology, 2010, 122, 74-81.	2.5	138
69	Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension. Diabetes Research and Clinical Practice, 2010, 89, 209-215.	2.8	14
70	Characterization of New PPARÎ³ Agonists: Analysis of Telmisartanâ€™s Structural Components. ChemMedChem, 2009, 4, 445-456.	3.2	38
71	Characterization of New PPARÎ³ Agonists: Benzimidazole Derivatives - the Importance of Positionâ€…2. ChemMedChem, 2009, 4, 1136-1142.	3.2	22
72	ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy. Journal of Hypertension, 2009, 27, S36-S39.	0.5	12

#	Article	IF	Citations
73	INT-131, a PPARgamma agonist for the treatment of type 2 diabetes. Current Opinion in Investigational Drugs, 2009, 10, 381-7.	2.3	13
74	Pharmacological Differences of Glitazones. Journal of the American College of Cardiology, 2008, 52, 882-884.	2.8	12
75	Metabolic Actions of Estrogen Receptor Beta (ERÎ²) are Mediated by a Negative Cross-Talk with PPARÎ³. PLoS Genetics, 2008, 4, e1000108.	3.5	241
76	Angiotensin II Type 2 Receptor Stimulation. Circulation, 2008, 118, 2523-2532.	1.6	250
77	Inhibiting angiotensin type 1 receptors as a target for diabetes. Expert Opinion on Therapeutic Targets, 2008, 12, 1257-1263.	3.4	26
78	Does adiponectin resistance exist in chronic heart failure?. European Heart Journal, 2007, 28, 1676-1677.	2.2	27
79	Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovascular Diabetology, 2007, 6, 12.	6.8	81
80	Regulation of Peroxisome Proliferatorâ€"Activated Receptor Î³ Activity by Losartan Metabolites. Hypertension, 2006, 47, 586-589.	2.7	86
81	Molecular Characterization of New Selective Peroxisome Proliferator-Activated Receptor Â Modulators With Angiotensin Receptor Blocking Activity. Diabetes, 2005, 54, 3442-3452.	0.6	270
82	PPARÎ³-Activating Angiotensin Type-1 Receptor Blockers Induce Adiponectin. Hypertension, 2005, 46, 137-143.	2.7	257
83	PPARÎ³-mediated insulin sensitization: the importance of fat versus muscle. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E287-E291.	3.5	196
84	Angiotensin II, PPAR-Gamma and atherosclerosis. Frontiers in Bioscience - Landmark, 2004, 9, 359.	3.0	31
85	Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferatorâ€"Activated Receptor-Î³ Activity. Circulation, 2004, 109, 2054-2057.	1.6	696
86	p38 MAP kinase negatively regulates angiotensin II-mediated effects on cell cycle molecules in human coronary smooth muscle cells. Biochemical and Biophysical Research Communications, 2003, 305, 552-556.	2.1	16
87	PPARÎ± Inhibits TGF-Î²â€"Induced Î² 5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad4. Circulation Research, 2002, 91, e35-44.	4.5	62
88	TGF-Î²1 induces peroxisome proliferator-activated receptor Î³1 and Î³2 expression in human THP-1 monocytes. Biochemical and Biophysical Research Communications, 2002, 297, 794-799.	2.1	22
89	Retinoids Inhibit Proliferation of Human Coronary Smooth Muscle Cells by Modulating Cell Cycle Regulators. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 746-751.	2.4	49
90	Doxazosin Inhibits Retinoblastoma Protein Phosphorylation and G 1 â†'S Transition in Human Coronary Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1216-1224.	2.4	24

#	Article	IF	Citations
91	Peroxisome Proliferator-activated Receptor Î³ Ligands Inhibit Retinoblastoma Phosphorylation and G1 â†’ S Transition in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2000, 275, 22435-22441.	3.4	195